Cargando…
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
BACKGROUND: Angiogenesis plays a role in tumor growth and is partly mediated by factors in both the fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) pathways. Durable clinical responses with VEGF tyrosine kinase inhibitors (TKIs) may be limited by intrinsic tumor resistan...
Autores principales: | Ho, Thai H, Liu, Xian-De, Huang, Yanqing, Warneke, Carla L, Johnson, Marcella M, Hoang, Anh, Tamboli, Pheroze, Wang, Fen, Jonasch, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406182/ https://www.ncbi.nlm.nih.gov/pubmed/25900027 http://dx.doi.org/10.1186/s12885-015-1302-1 |
Ejemplares similares
-
Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features
por: Sircar, Kanishka, et al.
Publicado: (2013) -
Cadherin-11 in Renal Cell Carcinoma Bone Metastasis
por: Satcher, Robert L., et al.
Publicado: (2014) -
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019) -
FRS2-independent GRB2 interaction with FGFR2 is not required for embryonic development
por: Clark, James F, et al.
Publicado: (2023) -
FRS2-independent GRB2 interaction with FGFR2 is not required for embryonic development
por: Clark, James F., et al.
Publicado: (2023)